19
Views
0
CrossRef citations to date
0
Altmetric
Review

Patent developments in anabolic agents for treatment of bone diseases

&
Pages 1141-1156 | Published online: 02 Mar 2005
 

Abstract

A review of the patent literature encompassing the past 3 years (~ 2000 – 2003) in the area of bone anabolic therapies for treatment of osteoporosis and related diseases is described. A variety of potential therapeutics are covered, as well as improvement attempts on the first approved bone anabolic agent, recombinant human parathyroid hormone (rPTH; teriparatide, Forteo®, Eli Lilly & Co.). The patent literature suggests that multiple strategies are currently being pursued in order to deliver the first orally bioavailable anabolic agent to the market and that a variety of new targets are also being evaluated for further development.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.